Innovation Pharmaceuticals Inc (IPIX)

[Cognition]

All done at zero cost to IPIX!

“Testing Brilacidin’s direct virucidal activity on SARS-CoV-2 in human lung epithelial cells (by preincubating the novel coronavirus with Brilacidin at varying concentrations and times of incubation);
Obtaining the in vitro concentration of Brilacidin that gives half-maximal response, the EC50 value, in lung epithelial cells;
Determining impact of multiple dose exposure of Brilacidin on SARS-CoV-2 (assessing potential for achieving greater virus control without inducing toxicity);
Evaluating time-to-treatment windows as a post-exposure therapeutic (by introducing Brilacidin at 4, 8, and 16 hours post-initial infection, with virus cultures carried forward up to 48 hours);
Exploring if Brilacidin has synergistic properties with other small molecules that have antiviral activity”.